

AWARD NUMBER: W81XWH-19-1-0774

TITLE: The Role of Astrocyte-Derived Tau Oligomers in Neurodegeneration Triggered by TBI.

PRINCIPAL INVESTIGATOR: Cristian Lasagna-Reeves, PhD.

CONTRACTING ORGANIZATION: Indiana University, Indianapolis, IN

REPORT DATE: October 2022

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2022		2. REPORT TYPE Annual		3. DATES COVERED 01Sep2021-31Aug2022	
4. TITLE AND SUBTITLE The Role of Astrocyte-Derived Tau Oligomers in Neurodegeneration				5a. CONTRACT NUMBER W81XWH-19-1-0774	
				5b. GRANT NUMBER AZ180006	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Cristian Lasagna-Reeves, PhD. E-Mail: clasagna@iu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) TRUSTEES OF INDIANA UNIVERSITY INDIANA UNIVERSITY IUPUI 980 INDIANA AVE RM 2232, INDIANAPOLIS IN 46202-5130				8. PERFORMING ORGANIZATION REPORT NUMBER 6030079020000	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT In AD, studies described a spatial and temporal pattern in the appearance of tau tangles in patient brains that follow neuronal networks and correlates with cognitive decline. While still a contentious topic, there is strong evidence that supports the idea that propagation of pathological tau species occurs between neurons. Microglia and astrocytes have recently been shown to be active participants in the pathological spreading of tau. Nevertheless, the functional significance of propagated glial tau remains to be established. Studies suggest that tau pathology propagation is one of the mechanisms underlying the long-term neurodegenerative effects after TBI. The mechanism by how tau propagation in TBI subsequently triggers AD/ADRD pathogenesis is still unknown. Studies have shown how tau appears to be required for A β to cause synaptic and cognitive deficits in AD. It was reported that complete ablation of tau prevents deficits in spatial learning and memory after repeated mild frontal impact in WT mice. These results support the idea that reduction of tau could ameliorate the detrimental effects responsible for the association between TBI and AD. Yet no studies have addressed the contribution of exclusively reducing astrocytic tau on reverting AD/ADRD pathogenesis linked to TBI. Hypothesis: Based in these observations in conjunction with our preliminary data, we hypothesize that vascular damage triggered by TBI induces astrocytic-tau aggregation that subsequently promotes tau spreading throughout the brain eliciting synaptotoxicity and neurodegeneration as observed in AD and AD-related dementias. Unfortunately, there is no clear understanding of the molecular and cellular mechanisms that underlie the contribution of astrocytic-tau aggregates to neurodegeneration and dementias associated to TBI.					
15. SUBJECT TERMS Mice					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
Unclassified	Unclassified	Unclassified	Unclassified	8	USAMRDC

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4-7
4. Impact	7-8
5. Changes/Problems	8
6. Products	8
7. Participants & Other Collaborating Organizations	8
8. Special Reporting Requirements	8
9. Appendices	8

1. Introduction

Aim 1. To characterize the effect of TBI in the disruption of astrocytes-vascular coupling and reactive astrogliosis in the context of tau pathophysiology.

Sub-aim 1A. Determine the role of astrocytic-tau pathology in the neurodegeneration and synaptotoxicity associated with TBI.

In this sub-aim, WT C57BL/6 mice will be exposed to CCI and sacrificed 3 or 135 DPI to study acute or chronic injury respectively. We will perform a series of pathological and biochemical analyses to determine tau modifications associated with astrogliosis and vascular damage. We will also determine which type of reactive astrocytes (A1 or A2) is related to tau pathology. Astrocytes will be isolated to determine astrocytic-tau post-translational modifications and aggregation due to TBI. Finally, we will determine if astrocyte-derived tau oligomers induce neuronal synaptotoxicity and hippocampal LTP impairment.

Sub-aim 1B. Evaluate the role of astrocyte-derived tau oligomers in pathological spreading of tau after TBI.

In the current sub-aim, we will isolate astrocytic-tau oligomers from mice exposed to CCI and determine their ability to spread tau pathology *in vitro* and *in vivo*. First, isolated astrocytic-tau oligomers from TBI and control groups will be analyzed using a novel Forster Resonance Energy Transfer (FRET)-based biosensor cell line that specifically reports tau seeding activity. Then, isolated astrocytic-tau oligomers will be injected intracerebrally into Htau mice that over-express human tau to establish if astrocytic-tau from TBI mice accelerate the onset of behavioral impairment and neurodegeneration and propagate tau pathology *in vivo*.

Aim2. Investigate if the ablation of astrocytic-tau attenuates neurodegeneration and tau propagation throughout the brain after TBI.

It was recently reported that complete ablation of murine endogenous tau prevents deficits in spatial learning and memory after repeated mild frontal impact in WT mice⁷⁷. Nevertheless, no studies have addressed the contribution of exclusively reducing astrocytic tau levels on TBI neurodegenerative associated phenotypes. Therefore, in this aim, we will investigate whether astrocytic tau works in concert or independently over tau spreading, pathology, glial activation, and neurodegeneration in mice subjected to TBI. Specifically, we will cross *Mapt*^{flox/flox} with GFAP-Cre mice to determine if the specific ablation of astrocytic endogenous tau may revert pathological and behavioral phenotypes associated with TBI. GFAP-Cre; *Mapt*^{flox/flox} and *Mapt*^{flox/flox} mice will be exposed to CCI and sacrificed 3 or 135 DPI to study acute or chronic injury respectively. Mice will be subjected to a series of pathological, biochemical, electrophysiological, and behavioral analyses.

2. Keywords

Tau, oligomers, astrocytes, propagation, TBI, AD, tauopathies, seeding, aggregation.

3. Accomplishments

3.a Goal of the project

- Define the role of astrocytic tau aggregates in the synaptotoxicity due to TBI.
- Define the role of astrocyte-derived tau oligomers on tau propagation due to TBI.

- Determine if ablation of functional endogenous astrocytic tau suppresses behavioral deficit and synaptotoxicity in a mouse model for TBI.

3.b Accomplishment under these goals

- As part of major task 1, subtask 3, we finalized the characterization of astrocyte-derived tau oligomers from mice expose to CCI. Astrocytes were isolated from Sham and CCI mice. Western blot analysis demonstrated how CCI induce an increase in the levels of astrocytic tau monomer (~49 KDa), the increase of a 64 KDa tau species and the induction of tau aggregation in the form of tau trimers (198 KDa). This astrocytic tau from Htau mice expose to CCI were used to perform the experiments described in figure 2.




Figure 1: Control Cortical Impact induced astrocytic tau aggregation. Western blot analysis revealed the increase in the levels of different astrocytic tau species do to brain trauma in comparison to Sham controls. Specificity of tau signal was confirmed by analyzing astrocytic preparation of Tau KO mice. I = Ipsilateral and C = Contralateral

- As part of major task 2, subtask 2, we stereotactically injected astrocytic tau from hTau mice expose to CCI into PS19 mouse model that over-express human with the P301S mutation. All mice were already injected. They are currently being age. As soon all mice turn 5 months, biochemical and histological analysis will be performed to determine if astrocytic-tau accelerated tau pathology in the PS19 model (Figure 2).




Figure 2: Schematic representation of astrocytic-tau in PS19 mice. Two-months old PS19 mice were injected with astrocytic lysate from hTau expose to CCI or SHAM control. Three months post-injection histological and biochemical analysis will be perform.

- As part of major task 3 subtask 2 and 3, we intracerebroventricularly injected hTau mice at P0 with AAV-GFAP-TOMATO-shRNA against human tau or shScramble. Five months post injection, mice were exposed to CCI or SHAM. Three days post-CCI mice were sacrificed. We are currently isolating astrocytes from these mice to determine if the astrocytic tau aggregates observed in hTau mice exposed to CCI (Figure 1) is due to endogenous astrocytic tau aggregation or neuronal tau.




Figure 3: Schematic representation of Major task 2 and 3. hTau mice were injected ICV at P0 with AAV-GFAP-TOMATO shRNA-Tau or scramble. Five months later mice were exposed to CCI. Three days post CCI mice were sacrificed for biochemical and histological analysis.

Animal Use Regulatory Protocols

TOTAL PROTOCOL(S):

PROTOCOL (1 of 1 total):

Protocol [ACURO Assigned Number]: AZ180006.e002

Title: The Role of Astrocyte-Derived Tau Oligomers in Neurodegeneration Triggered by TBI

Target required for statistical significance: NA

Target approved for statistical significance: NA

SUBMITTED TO AND APPROVED BY:

IACUC APPROVAL DATES: 07/08/2019 – 07/08/2022. PROTOCOL RENEW FROM 05/03/2022 – 05/03/2025

ACURO APPROVAL DAY: 01/30/2020

STATUS: APPROVED

3.c Opportunities for training.

Nothing to report.

3.d Results dissemination

During 2022, two papers were accepted for publication.

1. P. Martinez, H. Patel, Y. You, N. Jury, A. Perkins, A. Lee-Gosselin, X. Taylor, Y. You, G. Viana Di Prisco, X. Huang, S. Dutta, A. Wijeratne, J. Redding-Ochoa, S. Shahid, J. Codocedo, G. Landreth, A. Mosley, Y.C. Wu, D. McKinzie, J.C. Rochet, J. Zhang, B. Atwood, J. Troncoso and **C.A. Lasagna-Reeves**. Bassoon Contributes to Tau-seed Propagation and Neurotoxicity. **Nat Neurosci**. 2022 Dec;25(12):1597-1607. (Journal IF: 28.7)
Featured at Alzforum: <https://www.alzforum.org/news/research-news/bassoon-heralds-spread-toxic-tau>
2. P. Cisternas, X. Taylor, P. Martinez, N. Jury, O. Maldonado and **C.A. Lasagna-Reeves**. Astrocytic Tau Reduction Prevents Abeta-Induced Synaptotoxicity. **Brain Comm**. 2022 Sept 4;5 (fcac235)

3.e Plan for next report period.

For the next report period, we are planning to perform the experiments describe in Major Task 2 **subtask 3** and initiate the milestones described in Major Task 3 **subtask 4**.

Major Task 2 Subtask 2:

Stereotactically inject astrocyte-derived tau oligomers into brains of PS19 mice.

Major Task 2 Subtask 3:

Mice described in subtask 2 will be subjected to histopathological (n= 6) or biocehmical (n = 6) analysis.

Major Task 3 Subtask 4:

hTau mice injected with AAV-GFAP-TOMATO-shRNA-hTau and expose to CCI will be subjected to histological and biochemical analysis.

4. Impact

Traumatic brain injury (TBI) affects approximately 3.8 million people annually and costs the US more than \$48 million. Furthermore, TBI has become an increasingly common feature of modern military conflicts. It is estimated that in the Iraq and Afghanistan conflicts following the terrorist attacks of September 11, 2001, the rate of TBI in military populations has dramatically increased to upwards of 10-20% of those serving, with over 250,000 soldiers exposed to some form of TBI. The long-term consequences of TBI are multifaceted and include increased risk for Alzheimer's disease (AD). The burden of AD is enormous. It is estimated that over 30 million Americans will live with AD by 2050 due to the lack of effective treatments. To date, mechanisms linking TBI to AD remain unclear. Therefore, gaining a better understanding of the mechanism(s) responsible for the association between TBI and AD/ADRD is essential not only for the development of strategies for the intervention of dementias associated to TBI, but could also open new avenues for the treatment of all AD/ADRD cases.

This proposal is based on scientific evidence that cerebrovascular dysfunction, reactive astrogliosis, and pathological accumulation of tau protein has been observed in TBI, AD, and other ADRD known as tauopathies. Therefore, in the current proposal we attempt to link these three pathological hallmarks for TBI and AD/ADRD in order to identify the contributing mechanism associated with TBI and subsequent AD/ADRD. We are confident that a major outcome of the proposal will be to dissect in detail the mechanism by which TBI leads to vascular damage followed by astrocytic-tau aggregation that subsequently is released from astrocytes inducing pathological tau propagation, synaptotoxicity, and finally neurodegeneration. As short term gains, the experiments aligned here will allow us to validate the *vascular-astrocyte-tau* axis as a key player for the mechanism linking TBI to AD/ADRD. It will also prove decreasing astrocytic-tau levels as a feasible strategy to revert synaptotoxicity and neurodegeneration associated to TBI. In the long term, the mechanisms dissected in this proposal may

be expanded in the study of other neurodegenerative diseases not necessarily associated to TBI, since cerebrovascular dysfunction, reactive astrogliosis, and pathological accumulation of tau are common hallmarks of many other neurodegenerative dementias. It is also likely, due to scientific dissemination via publications or presentation, that other groups will continue dissecting with higher detail the exact mechanism of tau aggregation and release from astrocytes, increasing the number of molecular targets to revert synaptotoxicity and neurodegeneration associated to TBI.

Cumulatively, this study is devoted to understand the association between TBI and AD/ABR, and will focus on how the connection of tau pathology with the gliovascular unit, rather than a sole neuronal connection, is a key event in the development of dementias associated to brain trauma. Ultimately, the understanding of this mechanism will yield therapeutic targets for the treatment of dementias associated to TBI that will be extremely beneficial to the military and military veteran community affected by AD/ABR, their caregivers, and their families.

5. Changes/problems

During 2022, Miss Abby Perkins, the Research analyst leading this project and performing the CCI surgeries left my laboratory. Miss Perkins before leaving, she trained Miss Kathryn Vanderbosch that is currently performing the CC surgeries. Henika Patel a graduate student in the lab, is also working in this project by performing staining and biochemical analysis. Unfortunately, this changed in the project leadership slow us down by one quarter.

6. Products

No products have been produced at the moment

7. Participants & Other Collaborating Organizations

The entire project is being perform at Indiana University

8. Special Reporting Requirements

No special requirements are reported

9. Appendices